Shattuck Labs (STTK) Common Equity (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Common Equity of $95.8 million for Q1 2026, up 41.8% year-over-year from $67.6 million in Q1 2025, and up 16.32% quarter-over-quarter from $82.4 million in Q4 2025.
Shattuck Labs (STTK) Common Equity (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Common Equity for 8 consecutive years, with $95.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 41.8% year-over-year to $95.8 million; the TTM figure through Mar 2026 stood at $95.8 million (up 41.8% YoY), while the FY2025 annual figure was $82.4 million, up 3.47% from the prior year.
- Common Equity climbed to $95.8 million in Q1 2026 per STTK's latest filing, from $82.4 million in the prior quarter.
- Across five years, Common Equity topped out at $248.9 million in Q1 2022 and bottomed at $57.0 million in Q2 2025.
- Historically, Common Equity has averaged $130.1 million across 5 years, with a median of $112.8 million in 2023.
- Annual changes were most pronounced in 2025 — Common Equity tumbled 48.45% — and 2026, when it soared 41.8%.
- Shattuck Labs' Common Equity stood at $176.2 million in 2022, then declined by 17.85% to $144.7 million in 2023, then sank by 44.97% to $79.6 million in 2024, then increased by 3.47% to $82.4 million in 2025, then grew by 16.32% to $95.8 million in 2026.
- Business Quant data shows STTK's Common Equity at $95.8 million in Q1 2026, $82.4 million in Q4 2025, and $93.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | 211.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 211.14 Mn |
| Mar 31, 2026 | 95.84 Mn |
| Dec 31, 2025 | 82.39 Mn |
| Sep 30, 2025 | 93.24 Mn |
| Jun 30, 2025 | 57.02 Mn |
| Mar 31, 2025 | 67.59 Mn |
| Dec 31, 2024 | 79.63 Mn |
| Sep 30, 2024 | 96.58 Mn |
| Jun 30, 2024 | 110.62 Mn |
| Mar 31, 2024 | 128.81 Mn |
| Dec 31, 2023 | 144.71 Mn |
| Sep 30, 2023 | 112.78 Mn |
| Jun 30, 2023 | 138.46 Mn |
| Mar 31, 2023 | 157.65 Mn |
| Dec 31, 2022 | 176.16 Mn |
| Sep 30, 2022 | 199.42 Mn |
| Jun 30, 2022 | 222.53 Mn |
| Mar 31, 2022 | 248.94 Mn |
| Dec 31, 2021 | 271.79 Mn |
| Sep 30, 2021 | 261.17 Mn |